← 홈

CGT

1,235개 · ADC 1032 · Antibody 4683 · CGT 2713 · 다음 갱신 D-12 · 마지막 7월 21일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 1,235개
CGTSHOTFDACuratedFDABiologicKitevedotin plus bendamustine a…Approved

axicabtagene ciloleucel (Yescarta, axi-cel)

LBCL, FL · CD19

#CD19#CGT#Approved#FDA승인#바이오모아추천+5
효능 ORR 92%임상시험 66상태 APPROVED
CGTAHOTFDACuratedFDABiologicNovartisApproved

tisagenlecleucel (Kymriah, tisa-cel)

ALL, DLBCL, FL · CD19

#CD19#CGT#Approved#FDA승인#바이오모아추천+5
효능 ORR 82.3%임상시험 48상태 APPROVED
CGTAAVAHOTFDACuratedFDABiologicNovartisSMN1 cDNA under hybrid CMV …Approved

onasemnogene abeparvovec (Zolgensma, AVXS-101, onasemnogene abeparvovec-xioi)

Spinal muscular atrophy (SMA) Type 1–3, pediatric · SMN1 (AAV9)

#SMN1AAV9#CGT#Approved#FDA승인#바이오모아추천+5
임상시험 26상태 APPROVED
CGTAAVBHOTFDACuratedFDABiologicSarepta TherapeuticsMicro-dystrophin cassetteApproved

delandistrogene moxeparvovec (Elevidys, SRP-9001, delandistrogene moxeparvovec-rokl)

Duchenne muscular dystrophy (DMD) — ambulatory / label-expanded populations · Micro-dystrophin (AAVrh74)

#Micro-dystrophinAAVrh74#CGT#Approved#FDA승인#바이오모아추천+5
임상시험 12상태 APPROVED
CGTSHOTFDACuratedFDABiologicFerring PharmaceuticalsHuman interferon alfa-2bApproved

nadofaragene firadenovec (Adstiladrin, rAd-IFNα/Syn3, nadofaragene firadenovec-vncg)

High-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) · IFNα2b (adenoviral)

#IFN2badenoviral#CGT#Approved#FDA승인#바이오모아추천+5
효능 ORR 55%임상시험 10상태 APPROVED
CGTBHOTFDACuratedFDABiologicVertexApproved

exagamglogene autotemcel (Casgevy, exa-cel, CTX001)

Sickle cell disease with recurrent VOCs; transfusion-dependent β-thalassemia · BCL11A enhancer (CRISPR/Cas9) → HbF

#BCL11AenhancerCRISPRCas9HbF#CGT#Approved#FDA승인#바이오모아추천+5
임상시험 9상태 APPROVED
CGTAAVBHOTFDACuratedFDABiologicBioMarinB-domain deleted FVIIIApproved

valoctocogene roxaparvovec (Roctavian, BMN 270, valoctocogene roxaparvovec-rvox)

Severe hemophilia A in adults · Factor VIII (AAV5)

#FactorVIIIAAV5#CGT#Approved#FDA승인#바이오모아추천+5
임상시험 8상태 APPROVED
CGTAAVBHOTFDACuratedFDABiologicCSL BehringFactor IX Padua variant (hy…Approved

etranacogene dezaparvovec (Hemgenix, AMT-061, CSL222, etranacogene dezaparvovec-drlb)

Hemophilia B (congenital Factor IX deficiency) in adults · Factor IX (AAV5 Padua)

#FactorIXAAV5Padua#CGT#Approved#FDA승인#바이오모아추천+5
임상시험 7상태 APPROVED
CGTAAVBHOTFDACuratedFDABiologicSpark TherapeuticsHuman RPE65 cDNAApproved

voretigene neparvovec (Luxturna, AAV2-hRPE65v2, voretigene neparvovec-rzyl)

Inherited retinal dystrophy due to confirmed biallelic RPE65 mutations · RPE65 (AAV2)

#RPE65AAV2#CGT#Approved#FDA승인#바이오모아추천+5
임상시험 7상태 APPROVED
CGTCHOTFDACuratedFDABiologicbluebird bioβA-T87Q-globinApproved

lovotibeglogene autotemcel (Lyfgenia, lovo-cel, bb1111)

Sickle cell disease with recurrent vaso-occlusive events · βA-T87Q-globin (lentiviral)

#A-T87Q-globinlentiviral#CGT#Approved#FDA승인#바이오모아추천+5
임상시험 2상태 APPROVED
CGTBHotBiologicGlaxoSmithKlinePhase 1

19 (T2, 19, 19(T2)28z1xx TRAC T cell)

B-Cell Lymphoma; Large B-cell Lymphoma · B-Cell Lymphoma

#B-CellLymphoma#CGT#Phase1#인기#세포유전치료+5
효능 ORR 100%임상시험 234상태 RECRUITING
CGTCHotBiologicstaleThomas Martin, MDPhase 1

Chimeric Antigen Receptor T cells (CAR-T, Chimeric Antigen Receptor T cells, Chimeric Antigen Receptor T cells (CAR-T) Targeting BCMA)

Multiple Myeloma; Recurrent Multiple Myeloma · BCMA

#BCMA#CGT#Phase1#인기#세포유전치료+5
효능 ORR 97.1%임상시험 113상태 DISCONTINUED
CGTABiologicstaleAstraZenecaPhase 2

autologous CD19-directed chimeric antigen receptor (CAR, autologous CD19-directed chimeric antigen receptor, autologous CD19-directed chimeric antigen receptor (CAR) T-cells)

Relapsed Non Hodgkin Lymphoma; Relapsed Adult ALL · CD19

#CD19#CGT#Phase2#인기#세포유전치료+5
효능 ORR 77.3%임상시험 96상태 RECRUITING
CGTABiologicJanssen Research & Development,…Phase 3

AA (Abiraterone acetate, Abiraterone acetate (AA))

Metastatic Castration-sensitive Prostate Cancer · Metastatic Castration-sensitive Prostate

#MetastaticCastration-sensitivePr#CGT#Phase3#인기#세포유전치료+3
효능 ORR 57.1%임상시험 77상태 RECRUITING
CGTABiologicNational Cancer Institute (NCI)inPhase 1

Anti-B Cell Maturation Antigen (BCMA, Anti-B Cell Maturation Antigen, Anti-B Cell Maturation Antigen (BCMA) chimeric antigen receptors (CARs) T cells)

Myeloma-Multiple; Myeloma, Plasma-Cell · BCMA

#BCMA#CGT#Phase1#인기#세포유전치료+5
효능 ORR 97.1%임상시험 73상태 RECRUITING
CGTBBiologicstaleBioceltech Therapeutics, Ltd.Phase 1

CD19 CAR T cells (CD19 CAR T cells)

B-cell Acute Lymphoblastic Leukemia · CD19

#CD19#CGT#Phase1#인기#세포유전치료+5
효능 ORR 88%임상시험 73상태 RECRUITING
CGTCBiologicstaleIovance Biotherapeutics, Inc.Phase 2

TCR (E7 T Cell Receptor, E7 T Cell Receptor (TCR))

Papillomavirus Infections; Oropharyngeal Neoplasms · Squamous Lntraepithelial Lesions of Vulv

#SquamousLntraepithelialLesionsof#CGT#Phase2#인기#세포유전치료+5
효능 ORR 4%임상시험 69상태 DISCONTINUED
CGTBiologicstaleJuventas Cell Therapy Ltd.Phase 1

Anti-CD19 CAR T-cells (Anti-CD19 CAR T-cells)

Multi-Drug Resistant Nephrotic Syndrome; CAR-T Cell Therapy · CD19

#CD19#CGT#Phase1#인기#세포유전치료+5
효능 ORR 94%임상시험 68상태 ACTIVE
CGTBiologicstaleJuventas Cell Therapy Ltd.Phase 2

CD19 CAR-T (CD19 CAR-T)

B-cell Malignancy; B-cell Lymphoma · CD19

#CD19#CGT#Phase2#인기#세포유전치료+5
효능 ORR 88%임상시험 66상태 ACTIVE
CGTBiologicAmgenPhase 3

Asparaginase Erwinia chrysanthemi (Asparaginase Erwinia chrysanthemi, Asparaginase Erwinia chrysanthemi (recombinant)-rywn, recombinant)

Acute Lymphoblastic Leukemia; Acute Lymphoblastic Lymphoma · Acute Lymphoblastic Leukemia

#AcuteLymphoblasticLeukemia#CGT#Phase3#인기#세포유전치료+5
효능 ORR 18%임상시험 64상태 RECRUITING

1 / 62 페이지

← 이전다음 →